File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12955-023-02177-z
- Scopus: eid_2-s2.0-85168063120
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
Title | Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease |
---|---|
Authors | |
Keywords | EQ-5D-5 L Psychometric properties Reliability Responsiveness ThyPRO-39 Validity |
Issue Date | 15-Aug-2023 |
Publisher | BioMed Central |
Citation | Health and Quality of Life Outcomes, 2023, v. 21, n. 1 How to Cite? |
Abstract | Background: The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves' disease (GD). Methods: A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ-5D-5 L and ThyPRO-39 questionnaires at baseline, 1-month, and 6-month follow-ups. Convergent validity was tested by examining the Spearman correlation between EQ-5D-5 L and ThyPRO-39 scores at baseline. 1-month test-retest reliability was assessed by Intraclass Correlation Coefficient (ICC), Gwet's Agreement Coefficient 2 (AC2), and percentage agreement. Responsiveness of EQ-5D-5 L index and EQ-VAS scores was assessed using effect size statistics (standardized effect size [SES] and standardized response mean [SRM]). Results: Of 125 recruited patients, 101 (80.8%) and 100 (80.0%) patients were followed up at 1- and 6-month, respectively. For convergent validity, there was a moderate negative correlation between EQ-5D-5 L index or EQ-VAS score and ThyPRO-39 overall QoL-impact score (-0.350, -0.451), between EQ-VAS score and composite score (-0.483), and strong negative correlation between EQ-5D-5 L index score and composite score (-0.567). The Gwet's AC2 and percentage agreement were the highest in self-care (0.964 and 0.967), followed by mobility (0.952 and 0.962), usual activities (0.934 and 0.948), pain/discomfort (0.801 and 0.887), and anxiety/depression (0.788 and 0.882). The ICC for the EQ-5D-5 L index and the EQ-VAS was 0.707 and 0.700. For patients who reported having 'worsened' health at 6-month follow-up, the SES and SRM were - 0.66 and - 0.42 for EQ-5D-5 L index and - 1.15 and - 1.00 for EQ-VAS, respectively. Conclusions: The EQ-5D-5 L demonstrated convergent validity, test-retest reliability, and responsiveness to worsened health status among patients with GD. |
Persistent Identifier | http://hdl.handle.net/10722/331286 |
ISSN | 2021 Impact Factor: 3.077 2020 SCImago Journal Rankings: 1.084 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, X | - |
dc.contributor.author | Chan, WW | - |
dc.contributor.author | Tang, EH | - |
dc.contributor.author | Suen, AH | - |
dc.contributor.author | Fung, MM | - |
dc.contributor.author | Woo, YC | - |
dc.contributor.author | Liu, SY | - |
dc.contributor.author | Lam, CL | - |
dc.contributor.author | Luo, N | - |
dc.contributor.author | Wong, CK | - |
dc.contributor.author | Lang, BH | - |
dc.date.accessioned | 2023-09-21T06:54:22Z | - |
dc.date.available | 2023-09-21T06:54:22Z | - |
dc.date.issued | 2023-08-15 | - |
dc.identifier.citation | Health and Quality of Life Outcomes, 2023, v. 21, n. 1 | - |
dc.identifier.issn | 1477-7525 | - |
dc.identifier.uri | http://hdl.handle.net/10722/331286 | - |
dc.description.abstract | <p><strong>Background: </strong>The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves' disease (GD).</p><p><strong>Methods: </strong>A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ-5D-5 L and ThyPRO-39 questionnaires at baseline, 1-month, and 6-month follow-ups. Convergent validity was tested by examining the Spearman correlation between EQ-5D-5 L and ThyPRO-39 scores at baseline. 1-month test-retest reliability was assessed by Intraclass Correlation Coefficient (ICC), Gwet's Agreement Coefficient 2 (AC2), and percentage agreement. Responsiveness of EQ-5D-5 L index and EQ-VAS scores was assessed using effect size statistics (standardized effect size [SES] and standardized response mean [SRM]).</p><p><strong>Results: </strong>Of 125 recruited patients, 101 (80.8%) and 100 (80.0%) patients were followed up at 1- and 6-month, respectively. For convergent validity, there was a moderate negative correlation between EQ-5D-5 L index or EQ-VAS score and ThyPRO-39 overall QoL-impact score (-0.350, -0.451), between EQ-VAS score and composite score (-0.483), and strong negative correlation between EQ-5D-5 L index score and composite score (-0.567). The Gwet's AC2 and percentage agreement were the highest in self-care (0.964 and 0.967), followed by mobility (0.952 and 0.962), usual activities (0.934 and 0.948), pain/discomfort (0.801 and 0.887), and anxiety/depression (0.788 and 0.882). The ICC for the EQ-5D-5 L index and the EQ-VAS was 0.707 and 0.700. For patients who reported having 'worsened' health at 6-month follow-up, the SES and SRM were - 0.66 and - 0.42 for EQ-5D-5 L index and - 1.15 and - 1.00 for EQ-VAS, respectively.</p><p><strong>Conclusions: </strong>The EQ-5D-5 L demonstrated convergent validity, test-retest reliability, and responsiveness to worsened health status among patients with GD.</p> | - |
dc.language | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.ispartof | Health and Quality of Life Outcomes | - |
dc.subject | EQ-5D-5 L | - |
dc.subject | Psychometric properties | - |
dc.subject | Reliability | - |
dc.subject | Responsiveness | - |
dc.subject | ThyPRO-39 | - |
dc.subject | Validity | - |
dc.title | Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12955-023-02177-z | - |
dc.identifier.scopus | eid_2-s2.0-85168063120 | - |
dc.identifier.volume | 21 | - |
dc.identifier.issue | 1 | - |
dc.identifier.eissn | 1477-7525 | - |
dc.identifier.issnl | 1477-7525 | - |